Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC42 | P60953 | 3/20 | 0.56 |
| ▸ | RAC1 | P63000 | 3/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10398047 | 0.77 | NPC1 (0.53) | CDC42RAC1PTGS2PTGS1NPC1 | |
| SCHEMBL11003137 | 0.76 | PTGS2 (0.44) | CDC42RAC1PTGS2PTGS1NPC1 | |
| SCHEMBL10934382 | 0.75 | CDC42 (0.45) | CDC42RAC1PTGS2PTGS1NPC1 | |
| SCHEMBL9088673 | 0.74 | CDC42 (0.60) | CDC42RAC1PTGS2PTGS1NPC1 | |
| Ketorolac SCHEMBL23466702 | 0.72 | PTGS2 (1.00) | CDC42RAC1PTGS2PTGS1NPC1 | |
| Ketorolac SCHEMBL14892 | 0.72 | PTGS2 (1.00) | CDC42RAC1PTGS2PTGS1NPC1 | |
| Ketorolac SCHEMBL4103 | 0.72 | PTGS2 (1.00) | CDC42RAC1PTGS2PTGS1NPC1 | |
| SCHEMBL10398048 | 0.72 | CDC42 (0.57) | CDC42RAC1PTGS2PTGS1NPC1 | |
| Ketorolac SCHEMBL15661224 | 0.71 | PTGS2 (0.97) | CDC42RAC1PTGS2PTGS1NPC1 | |
| Ketorolac SCHEMBL20553125 | 0.71 | PTGS2 (0.97) | CDC42RAC1PTGS2PTGS1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192571-B2 | Ketorolac tromethamine compositions for treating or preventing ocular pain | ALLERGAN, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-7879901-B2 | Sublingual Formulations of Ketorolac or Salts Thereof | NATURE'S PLUS FARMACEUTICA LTDA. (BR) | 2011-02-01 | — | — | US | disclosed |
| US-20100087503-A1 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN | ALLERGAN, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-1633342-B1 | PHARMACEUTICAL COMPOSITION BASED ON KETOROLAC OR ONE OF ITS SALTS PHARMACEUTICALLY ACCEPTABLE AND USE OF KETOROLAC OR ITS SALTS IN PHARMACEUTICAL COMPOSITIONS | NATURE S PLUS FARMACEUTICA LTD (BR) | 2010-04-07 | — | — | EP | disclosed |
| EP-1633342-A4 | PHARMACEUTICAL COMPOSITION BASED ON KETOROLAC OR ONE OF ITS SALTS PHARMACEUTICALLY ACCEPTABLE AND USE OF KETOROLAC OR ITS SALTS IN PHARMACEUTICAL COMPOSITIONS | NATURE S PLUS FARMACEUTICA LTD (BR) | 2008-03-05 | — | — | EP | disclosed |
| US-20060128782-A1 | Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions | NATURE'S PLUS FARMACEUTICA LTDA. (BR) | 2006-06-15 | — | — | US | disclosed |
| EP-1633342-A2 | PHARMACEUTICAL COMPOSITION BASED ON KETOROLAC OR ONE OF ITS SALTS PHARMACEUTICALLY ACCEPTABLE AND USE OF KETOROLAC OR ITS SALTS IN PHARMACEUTICAL COMPOSITIONS | Nature's Plus Farmacêutica Ltda. (BR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105678-A2 | PHARMACEUTICAL COMPOSITION BASED ON KETOROLAC OR ONE OF ITS SALTS PHARMACEUTICALLY ACCEPTABLE AND USE OF KETOROLAC OR ITS SALTS IN PHARMACEUTICAL COMPOSITIONS | NATURE'S PLUS FARMACÊUTICA LTDA. (BR) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128782-A1 | Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions | SI, SORD, KHK | CDC42 2827/4885RAC1 2927/4885PTGS2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.